Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Adipex-P

(Phentermine)

ApprovedSmall molecule

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phentermine is a prescription medication used to help people lose weight by reducing appetite and increasing energy. It's typically prescribed for short-term use (a few weeks to months) as part of a weight loss program for people who are obese or overweight.[2] Adipex-P is currently approved and in use across 6 indications[4].[1]

Adipex-P is one of 219 small molecule programs targeting Kidney Disease. It is currently in Approved.

6

Indications

24

Total Trials

3

Active Trials

218

Competitors

3

FDA Applications

NDA/BLA/ANDA regulatory filings

1

Patents

Pipeline

Status by Indication[4][1]

Indication

Kidney DiseaseApproved

Cocaine DependenceActive, not recruiting

Weight LossActive, not recruiting

Diabetes MellitusApproved

Liver DiseaseApproved

ObesityActive, not recruiting

Kidney DiseaseApproved

Approved

Cocaine DependencePhase 1

Active, not recruiting

Weight LossPhase 1

Active, not recruiting

Diabetes MellitusApproved

Approved

Liver DiseaseApproved

Approved

ObesityPhase 3

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Adipex-P

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Actemra

Avapro

Colcrys

Alnylam Pharmaceuticals

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cetrotide

Advil

Spiriva

Boehringer Ingelheim

Flagyl

DDePuy Orthopaedics

Prometrium

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Bariatric Surgery

NCT05975580

Q1 2028

Phase 2Not yet recruiting

Treatment

NCT07282340

Clinical

Trials by Indication[1]

Bariatric Surgery4 trials

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

Recruiting·UUniversity of California, Irvine·Phase 4·NCT05975580·120 enrolled

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

Completed·UUniversity of Colorado, Denver·Phase 2·NCT04095104·13 enrolled

Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery

Completed·HHospital Juarez de Mexico·Phase 4·NCT03849729·92 enrolled

Show 1 more trial

Medications After Adolescent Bariatric Surgery

Withdrawn·JJaney Pratt·Phase 2·NCT04572217

Obesity4 trials

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Completed·VVIVUS LLC·Phase 3·NCT00563368·756 enrolled

Individualized Obesity Pharmacotherapy

Completed·MMayo Clinic·Phase 3·NCT03374956·193 enrolled

Show 1 more trial

Cardiovascular System in Obesity: Effect of Treatment

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000506

Overweight4 trials

A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Completed·VVIVUS LLC·Phase 4·NCT05215418·565 enrolled

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02243202·335 enrolled

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00402077·258 enrolled

Show 1 more trial

Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity

Completed·TThe Cleveland Clinic·Phase 4·NCT04614545·70 enrolled

Weight loss3 trials

Phentermine/Gastric Band Weight Loss Study

Withdrawn·WWake Forest University Health Sciences·N/A·NCT00771654

The Effect of Phentermine and B12 on Weight Loss Among Obese Patients

Completed·—·Phase 1·NCT01719185·22 enrolled

Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

Completed·UUniversity of Pennsylvania·Phase 4·NCT03779048·147 enrolled

Abuse Potential3 trials

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 1·NCT01500018

Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users

Completed·BBioprojet·Phase 1·NCT03152123·43 enrolled

A Study to Evaluate Abuse Potential of Istradefylline

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1·NCT02609477·42 enrolled

6 more indications

Adult1 trial

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

Completed·VVIVUS LLC·Phase 1·NCT00518466·64 enrolled

Cocaine Dependence1 trial

Topiramate-Phentermine Combinations for Cocaine Dependence

Completed·UUniversity of Kentucky·Phase 1·NCT02239913·38 enrolled

Treatment1 trial

Phentermine's Impact on Treatment in Teens

Not yet recruiting·—·Phase 2·NCT07282340·240 enrolled

Caloric Restriction1 trial

Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)

Completed·—·N/A·NCT01616082·39 enrolled

Liraglutide1 trial

Lifestyle Modification and Liraglutide

Completed·UUniversity of Pennsylvania·Phase 4·NCT02911818·150 enrolled

Unspecified1 trial

Studying the Effects of Phentermine on Eating Behavior

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01886937·13 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

FASTIN

NDA NDA017352

Jan 1, 1982

WILPO

NDA NDA012737

Jun 13, 2011

SUPRENZA

NDA NDA202088

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Phentermine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Adipex-P drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Phentermine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Phentermine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202088). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Adipex-P. U.S. Food & Drug Administration.
[7]
SEC EDGAR — McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Norepinephrine Transporter Releasing Agent[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Patent Landscape[6]

Patent Cliff

Mar 14, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8440170Mar 14, 2029

Related News